Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents?
TA Rasmussen, SR Lewin - Current Opinion in HIV and AIDS, 2016 - journals.lww.com
TA Rasmussen, SR Lewin
Current Opinion in HIV and AIDS, 2016•journals.lww.comMore effective latency-reversing interventions and additional strategies to eliminate virus-
expressing cells are needed. Key challenges include testing combinations of LRAs and/or
LRAs with immune modulation to optimize potency in the absence of adverse events. A
better understanding of the mechanisms of action of LRAs as well as strategies to enhance
potency and penetration in tissue are key challenges for future studies.
expressing cells are needed. Key challenges include testing combinations of LRAs and/or
LRAs with immune modulation to optimize potency in the absence of adverse events. A
better understanding of the mechanisms of action of LRAs as well as strategies to enhance
potency and penetration in tissue are key challenges for future studies.
Summary
More effective latency-reversing interventions and additional strategies to eliminate virus-expressing cells are needed. Key challenges include testing combinations of LRAs and/or LRAs with immune modulation to optimize potency in the absence of adverse events. A better understanding of the mechanisms of action of LRAs as well as strategies to enhance potency and penetration in tissue are key challenges for future studies.
Lippincott Williams & Wilkins